ID   KY-Ra
AC   CVCL_W294
DR   cancercelllines; CVCL_W294
DR   Wikidata; Q54900771
RX   CelloPub=CLPUB00209;
RX   PubMed=8387619;
RX   PubMed=12716468;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Brain, meninges; UBERON=UBERON_0010743.
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1346 ! KY821
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 16
//
RX   CelloPub=CLPUB00209;
RA   Kakihara T.;
RT   "The characterization of highly resistant human leukemic cell lines to
RT   1-beta-D-arabinofuranosylcytosine.";
RL   Acta Med. Biol. 39:119-127(1991).
//
RX   PubMed=8387619; DOI=10.1016/0145-2126(93)90019-H;
RA   Fukuda T., Kakihara T., Kamishima T., Ohnishi Y., Naito M., Kishi K.,
RA   Shibata A.;
RT   "Different effects of various hematopoietic growth factors on
RT   myelomonocytic cell line (KY-821) and its drug-resistant sublines.";
RL   Leuk. Res. 17:325-332(1993).
//
RX   PubMed=12716468; DOI=10.1111/j.1349-7006.2002.tb01336.x; PMCID=PMC5927113;
RA   Shimizu H., Fukuda T., Ghazizadeh M., Nagashima M., Kawanami O.,
RA   Suzuki T.;
RT   "Molecular cytogenetic characterization of drug-resistant leukemia
RT   cell lines by comparative genomic hybridization and fluorescence in
RT   situ hybridization.";
RL   Jpn. J. Cancer Res. 93:902-910(2002).
//